Literature DB >> 25398277

Stratification of Contemporary Patients Undergoing Radical Prostatectomy for High-risk Prostate Cancer.

Jung Ki Jo1, Ha Rim Kook, Seok-Soo Byun, Sang Eun Lee, Sung Kyu Hong.   

Abstract

PURPOSE: Published data have shown heterogeneous outcomes for high-risk prostate cancer. Thus, we tried to identify more precise risk stratification system for contemporary high-risk prostate cancer.
METHODS: Classifying patients according to National Comprehensive Cancer Network risk groups, we reviewed data of 1,905 men who underwent radical prostatectomy (RP) at our institution from 2006 to 2013. For our analyses, high-risk prostate cancers meeting at least one of two following factors were categorized as unfavorable high-risk prostate cancer: biopsy primary Gleason pattern 5 and/or multiple (≥2) high-risk criteria present. All other men with high-risk prostate cancer were designated as having favorable high-risk disease. Postoperative outcomes, including biochemical recurrence-free survivals were assessed and compared via log-rank test and Cox proportional hazards model.
RESULTS: In multivariable analysis, primary Gleason 5 pattern on biopsy (p = 0.008) and multiple (≥2) high-risk criteria (p < 0.001) were observed to be independent predictors of the risk of biochemical recurrence amongst high-risk group undergoing RP. Favorable high-risk prostate cancer group showed a significantly higher 5-year biochemical recurrence-free survival than unfavorable high-risk group (56.35 vs. 18.75 %; log-rank test: p < 0.001). Favorable high-risk group demonstrated significantly lower 5-year biochemical recurrence-free survival than intermediate-risk group (56.07 vs. 82.05 %; log-rank test: p < 0.001).
CONCLUSIONS: A significant heterogeneity existed in biochemical outcomes of contemporary patients with high-risk prostate cancer who underwent definitive RP. According to primary Gleason pattern and number of high-risk criteria present, high-risk group should be stratified further into favorable and unfavorable disease.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25398277     DOI: 10.1245/s10434-014-4183-7

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  5 in total

1.  Biopsy Detected Gleason Pattern 5 is Associated with Recurrence, Metastasis and Mortality in a Cohort of Men with High Risk Prostate Cancer.

Authors:  Sean P Stroup; Daniel M Moreira; Zinan Chen; Lauren Howard; Jonathan H Berger; Martha K Terris; William J Aronson; Matthew R Cooperberg; Christopher L Amling; Christopher J Kane; Stephen J Freedland
Journal:  J Urol       Date:  2017-07-11       Impact factor: 7.450

2.  Biochemical Recurrence Prediction in High-Risk Prostate Cancer Patients, Following Robot-Assisted Radical Prostatectomy.

Authors:  Noriya Yamaguchi; Tetsuya Yumioka; Hideto Iwamoto; Toshihiko Masago; Shuichi Morizane; Masashi Honda; Takehiro Sejima; Atsushi Takenaka
Journal:  Yonago Acta Med       Date:  2016-12-26       Impact factor: 1.641

Review 3.  Radical Prostatectomy for High-risk Localized or Node-Positive Prostate Cancer: Removing the Primary.

Authors:  Justin T Matulay; G Joel DeCastro
Journal:  Curr Urol Rep       Date:  2017-07       Impact factor: 3.092

4.  Prostate MRSI predicts outcome in radical prostatectomy patients.

Authors:  Kristen L Zakian; William Hatfield; Omer Aras; Kun Cao; Derya Yakar; Debra A Goldman; Chaya S Moskowitz; Amita Shukla-Dave; Yousef Mazaheri Tehrani; Samson Fine; James Eastham; Hedvig Hricak
Journal:  Magn Reson Imaging       Date:  2016-01-26       Impact factor: 2.546

5.  Re-stratification of Patients with High-Risk Prostate Cancer According to the NCCN Guidelines among Patients Who Underwent Radical Prostatectomy: An Analysis Based on the K-CaP Registry.

Authors:  Kwang Suk Lee; Kyo Chul Koo; In Young Choi; Ji Youl Lee; Jun Hyuk Hong; Choung-Soo Kim; Hyun Moo Lee; Sung Kyu Hong; Seok-Soo Byun; Koon Ho Rha; Byung Ha Chung
Journal:  Cancer Res Treat       Date:  2017-03-07       Impact factor: 4.679

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.